rss
Br J Ophthalmol 93:614-621 doi:10.1136/bjo.2008.145193
  • Clinical science
    • Original Article

Molecular analysis of the ABCA4 gene for reliable detection of allelic variations in Spanish patients: identification of 21 novel variants

Open Access
  1. J Aguirre-Lamban1,2,
  2. R Riveiro-Alvarez1,2,
  3. S Maia-Lopes3,
  4. D Cantalapiedra1,2,
  5. E Vallespin1,2,
  6. A Avila-Fernandez1,2,
  7. C Villaverde-Montero1,2,
  8. M J Trujillo-Tiebas1,2,
  9. C Ramos1,2,
  10. C Ayuso1,2
  1. 1
    Genetics Department, Fundacion Jimenez Diaz, Madrid, Spain
  2. 2
    Centro de Investigacion Biomedica en Red de Enfermedades Raras (CIBERER), ISCIII, Madrid, Spain
  3. 3
    Visual Neuroscience Laboratory, IBILI, Faculty of Medicine, Coimbra, Portugal
  1. Dr J Aguirre-Lamban, Fundacion Jimenez Diaz, Genetics Department, Reyes Catolicos 2, 28.040 Madrid, Spain; jaguirre{at}fjd.es
  • Accepted 6 October 2008
  • Published Online First 21 November 2008

Abstract

Background/aims: Mutations in ABCA4 have been associated with autosomal recessive Stargardt disease (STGD), a few cases with autosomal recessive cone–rod dystrophy (arCRD) and autosomal recessive retinitis pigmentosa (arRP). The purpose of the study was threefold: to molecularly characterise families with no mutations or partially characterised families; to determine the specificity and sensitivity of the genotyping microarray; and to evaluate the efficiency of different methodologies.

Methods: 23 STGD, five arCRD and three arRP Spanish patients who were previously analysed with the ABCR400 microarray were re-evaluated. Results were confirmed by direct sequencing. In patients with either none or only one mutant allele, ABCA4 was further analysed by denaturing high-performance liquid chromatography (dHPLC) and multiplex ligation-dependent probe amplification (MLPA). Haplotype analysis was also performed.

Results: In the first analysis performed with the microarray, 27 ABCA4 variants (27/62; 43.5%) were found. By dHPLC scanning, 12 novel mutations were additionally identified. In addition, two previously described mutations, one false negative (1/62; 1.6%) and one false positive (1.6%), were detected. MLPA analysis did not reveal additional substitutions. The new strategy yielded an increment of 21% compared with the approach used in the first round.

Conclusion: ABCA4 should be analysed by optimal combination of high-throughput screening techniques such as microarray, dHPLC and direct sequencing. To the best of our knowledge, this strategy yielded significant mutational spectrum identification in Spanish patients with ABCA4-associated phenotypes. Follow-up of patients, presenting an early onset of the disease and severe mutations, seems essential to perform accurate genotype–phenotype correlations and further characterisation of pathological ABCA4 alleles.

Footnotes

  • Competing interests: None.

  • Funding: Thanks to FIS (Sanitary Research Fund) 06/0027, Fundacion Mutua Madrileña (30171/005), CIBERER (06/07/0036) and EviGenoRet LSHG-CT-2005-512036 for their support. JA-L’s work is supported by FIS from the Instituto de Salud Carlos III (PI06/0027).

  • Ethics approval: Ethics approval was provided by the Ethics Committee of the Hospital (Fundacion Jimenez Diaz).

  • Patient consent: Obtained.

  • This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Open Access

Register for free content


Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of BJO.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article